MediPharm Labs Corp. LABS MEDIF MLZ generated C$6.1 million ($4.85 million) in the fourth quarter of 2020, up by 22% sequentially.
The Barrie, Ontario-based company, wrapped up 2020 with C$36 million in revenue.
The bet loss amounted to roughly C$30.9 million for the quarter, compared to C$15.4 million in the prior period. For the full year, the net loss was C$72.1 million.
The company posted negative adjusted EBITDA (a non-IFRS measure) of C$8.7 million, compared to a C$7.26 million loss in the third quarter of 2020.
Adjusted EBITDA for the full year also came in in the red, at a loss of approximately C$23.9 million.
As of December 31, MediPharm had C$19.9 million in cash and cash equivalents.
The recently closed bought deal offering of 57.5 million units sold at 58 cents per unit brought in an additional C$33.4 million in financing.
MediPharm said it would utilize the proceeds to fund the development of its product portfolio, pharmaceutical registrations, and sales and marketing, to name a few.
"We are encouraged by the sequential increase in fourth-quarter revenue reflecting the growth of our manufacturing and white label business," the company's CFO Greg Hunter said Wednesday.
In October, the company teamed up with Sunco Green Pharmaceutical Pty Ltd to supply the Australian medical cannabis market and New Zealand with GMP-certified cannabis products.
The two-year white-label agreement was MediPharm's 12th deal to supply Australia with cannabis.
Meet the biggest cannabis industry players and make deals that will push the industry forward.
Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.
Join us September 13-14, 2022 at The Palmer House in Chicago, IL.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.